TA Associates Announces Strategic Growth Investment in Elos Medtech
TA Associates, a leading global growth private equity firm, today announced it has completed a majority growth investment in Elos Medtech AB (NASDAQ STOCKHOLM: ELOS B), a leading innovative full-service contract development and manufacturing organization (CDMO) in the global medical device market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005835/en/
Founded in 1923, Elos Medtech is headquartered in Gothenburg, Sweden with operations being conducted at facilities in Sweden, Denmark, China and the U.S. As a global solutions partner offering complete performance and vertical integration to leading medical device companies worldwide, Elos Medtech serves the dental, orthopaedic and life science markets. In long-term partnership with their customers, Elos Medtech provides sustainable and innovative products and supply solutions for the global medical device and life science market.
“We have followed Elos Medtech for several years and have been highly impressed by the company and its management team,” said Lovisa Lander, a Principal at TA. “Given its well-earned reputation for quality and reliability, we believe Elos Medtech is well-positioned to further grow market share as a partner of choice for leading medical technology and life science companies around the world. With our knowledge, network and financial resources, we believe that TA can support the investments that will be required to help the company continue its growth journey. We look forward to working with the Elos Medtech team to solidify its position as a global, high-quality development and manufacturing partner with a MedTech focus.”
“I am very pleased to welcome TA as the majority shareholder of Elos Medtech,” said Jan Wahlström, CEO of Elos Medtech. “Having completed more than 70 investments in healthcare businesses, including many in the medical device field, TA has the deep experience, network and global resources that we believe will prove highly beneficial at this stage of our growth. I thank all our shareholders as well as our skilled and motivated employees for their support of Elos Medtech and look forward to a close partnership with TA as we continue to further build a strong global group.”
“With a focus on innovation and precision, Elos Medtech has proven highly adept at meeting the varied demands and requirements of its target markets with turnkey solutions that add substantial value,” said Birker Bahnsen, a Managing Director at TA. “In line with the unanimous recommendation by the company’s board of directors, we believe that TA is well placed to support the investments required in the next phase of Elos Medtech’s journey. As long-term investors, we welcome the opportunity to help the company achieve its strategic goals and reach its full potential.”
Roschier served as legal counsel to TA.
Details of the Transaction
On June 11, 2021, TA (through a newly established company under name change to EM Intressenter AB) announced a public offer to the shareholders of Elos Medtech to tender all their shares in Elos Medtech to EM Intressenter for SEK 215 per share. On July 7, 2021, TA announced that the Offer would be completed and that the initial acceptance period, which ended on July 5, 2021, would be extended and open until July 14, 2021. The total amount of shares tendered in the Offer at the end of the extended acceptance period on July 14, 2021 amount in aggregate to approximately 79.5 per cent of the share capital and 65.0 per cent of the voting rights in Elos Medtech.
About Elos Medtech AB
Elos Medtech is a leading development and production partner for medical devices. Elos Medtech offers innovative comprehensive solutions, from concept to finished project, through its Complete Performance™ concept. Elos Medtech is active in the dental, orthopaedics, and life science market segments. For more information, please visit www.elosmedtech.com.
About TA Associates
TA is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – the firm invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 535 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $47.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $3 billion per year. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.
No United States of America securities regulatory authority has either approved or disapproved of the contents of this news release. This news release does not constitute an offer to sell, or a solicitation to buy, any securities of Elos Medtech in the United States of America or any other jurisdiction in which such offer or solicitation would be unlawful.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Speech Processing Solutions (SPS) becomes a Nuance Dragon Medical One Distributor in Europe and Asia Pacific Region28.9.2021 09:02:00 CEST | Press release
Speech Processing Solutions (SPS), a leader in professional dictation, has announced they are joining forces with Nuance Communications as an official distributor of Nuance Dragon Medical One, the leading cloud-based speech recognition solution for clinical documentation, in Europe and Asia Pacific Regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005069/en/ © Philips Dictation (Photo: Business Wire) One-stop shop for all voice-to-text needs This agreement enables SPS to become a one-stop-shop for healthcare solution partners and resellers providing dictation, speech recognition, and transcription software, as well as all hardware needs. The Nuance Dragon Medical One solution, which allows clinicians to document the complete patient record by voice, can now be easily combined with leading dictation workflow software and dictation hardware, such as the leading Philips SpeechMike line-up. Dr. Thomas Brauner, CEO of
Tigo Energy to Reveal New Solutions for Solar Fleet Management and Fire Safety at Intersolar Europe28.9.2021 09:00:00 CEST | Press release
Tigo Energy, Inc., the solar industry’s worldwide leader in Flex MLPE (Module Level Power Electronics), confirms the Company’s presence at the upcoming Intersolar Europe in Munich, Germany. Tigo representatives will showcase the entire family of Tigo TS4 Flex MLPE devices, including the recently introduced TS4-A-2F and the Tigo Energy Intelligence software platform. Together, these Tigo products make up the most cost-effective and advanced solution for rapid shutdown on large-scale solar projects. Tigo Energy has led solar innovation with its Tigo TS4 Flex MLPE by providing the freedom for customers to choose the features and components for their solar installations. Over the past 12 months, Tigo released key updates and innovations to its Flex MLPE product line to address the growing demand for high-power solar modules and energy projects that call for a diversified set of fire safety, monitoring, management, and power optimization features. “The Tigo TS4 is a fixture in the systems w
Galderma to Unveil Ground-breaking Data From Across Its Leading Dermatology Portfolio and Showcase Major Update for Sensitive Skincare Brand CETAPHIL ® at the 2021 EADV Congress28.9.2021 08:30:00 CEST | Press release
Galderma’s presence at the 2021 European Academy of Dermatology and Venereology (EADV) virtual congress on September 29 – October 2 will reveal new data and showcase the company’s sophisticated portfolio and services across the spectrum of dermatology. The company’s redesigned virtual booth will have dedicated areas presenting Galderma’s innovations in Consumer Care and Prescription Medicine. Unveiling new data in Prescription Medicine The congress will see the unveiling of exciting new data from Galderma relating to rosacea, acne, actinic keratosis, atopic dermatitis and prurigo nodularis. Attendees will have the opportunity to ask questions to the faculties during live Q&A sessions. On Thursday, September 30, Professor Alison Layton^ will chair the symposium Personalizing Acne: Consensus of Experts to Optimize Acne Management. Together with her co-speakers, Professor Layton will provide practical solutions for longitudinal management of acne. On the same day, Professor Gil Yosipovitc
ThreatConnect Expands Into South Africa, Partnering With Leading MSSP28.9.2021 07:00:00 CEST | Press release
ThreatConnect, Inc.®, the leader in reducing complexity and enabling better decision-making in cybersecurity, announced that it has entered a strategic partnership with BUI, Microsoft’s largest Security and Consulting Partner in South Africa. BUI is an award-winning Microsoft Azure Expert MSP, a member of the Microsoft Intelligent Security Association, and a Gold Microsoft Partner delivering cloud and security solutions, as well as professional services, in SA and across the world. With Cyber Risk Quantification (CRQ), Threat Intelligence Platform (TIP) and Security Orchestration, Automation, and Response (SOAR) capabilities combined, ThreatConnect unifies the actions of the security team around the most critical tasks, supports their response with streamlined and automated workflows, and strengthens the entire security ecosystem through powerful technology integrations. With ThreatConnect’s comprehensive intelligence-driven SOAR, BUI (among other MSSPs) sees a plethora of immediate be
GlobalLogic Launches Collaborative Hub Based in Lumada Innovation Hub Tokyo28.9.2021 02:00:00 CEST | Press release
Hitachi, Ltd. (TSE: 6501, “Hitachi”) and GlobalLogic*1, a Hitachi Group Company, today announced the launch of a collaborative hub to promote digital transformation (DX) services in the Japanese market. Based in the Lumada Innovation Hub Tokyo*2, a co-creation base for Hitachi, this collaboration hub combines capabilities of GlobalLogic and Lumada. Delivering on the joint integration strategy, this partnership aims to jump-start GlobalLogic’s entry into Japan, and will accelerate business development for design-led Digital Engineering services of GlobalLogic, establishing a system to support customers in Japan starting from fiscal 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005848/en/ A workshop connecting “Lumada Innovation Hub Tokyo” and GlobalLogic's Design and Engineering Centers. (Photo: Business Wire) "The market demand for DX continues to grow at a fast pace, as global brands increasingly leverage digit
SpeeDx and SynGenis Partner for Custom Oligonucleotide Synthesis28.9.2021 00:00:00 CEST | Press release
SpeeDx Pty, Ltd. a developer of innovative molecular diagnostic solutions announced investment in SynGenis Pty Ltd., an experienced oligonucleotide manufacturer based in Western Australia. The partnership will bolster internal capacity of SpeeDx to support large-scale increases in manufacturing while developing and expanding sovereign capacity of important raw materials used in molecular diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005329/en/ In addition to securing local supply chain to strengthen sovereign capacity for critical diagnostics and a more robust national health infrastructure, SpeeDx investment in local industry serves to fast track the growth and reach of SynGenis in the global diagnostics market. (Graphic: Business Wire) “We have invested considerable resources into our production scale-up processes to support the increase in testing seen as a result of the global pandemic,” said Tom Lin,
Medidata Veterans Rama Kondru and Sastry Chilukuri Named co-CEOs27.9.2021 23:00:00 CEST | Press release
Medidata, a Dassault Systèmes company, recently named Rama Kondru and Sastry Chilukuri co-CEOs. Both are Medidata veterans, with Chilukuri as the founding president of Medidata Acorn AI and Kondru as executive vice president and chief technology officer. Collaborating as CEOs will be nothing new for these industry leaders, having also partnered in roles prior to joining Medidata. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005812/en/ Medidata co-CEOs Sastry Chilukuri and Rama Kondru (l, r) (Photo: Business Wire) Chilukuri commented: “The life sciences industry is undergoing a sea change spurred by biological and technological innovation. We at Medidata are committed to being a trusted partner who helps customers deploy cutting-edge technology, data and AI to solve the impossible for patients.” Kondru commented: "We are excited to build the next chapter of Medidata around three critical pillars: a unified platform co